Price
No data yet.
Social Signal Score
Analyst Ratings
10 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Jared Kelly
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 29
- Beta
- 1.16
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -95.00
Financials
Net Income
$-9.44MEBITDA
$-9.33MFree Cash Flow
$-8.07MEPS (diluted)
$-0.08Shares Outstanding (diluted)
119.74M+843.6%Operating Expenses
$9.38MCash & Debt
$4.12MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-28.76M | $-0.41 |
| 2024 | $0.00 | $-22.79M | $-0.30 |
| 2023 | $0.00 | $-20.92M | $-0.41 |
| 2022 | $0.00 | $-18.30M | $-0.44 |
| 2021 | $0.00 | $-26.30M | $-0.49 |
| 2020 | $0.00 | $-22.50M | $-0.48 |
| 2019 | $0.00 | $-45.55M | $-1.50 |
| 2018 | $0.00 | $-17.04M | $-1.06 |
| 2017 | $0.00 | $-15.62M | $-1.12 |
| 2016 | $0.00 | $-15.14M | $-1.20 |
| 2015 | $0.00 | $-13.72M | $-1.16 |
| 2014 | $0.00 | $-18.62M | $-2.01 |
| 2013 | $0.00 | $-23.53M | $-2.68 |
| 2012 | $4.85M | $-36.37M | $-4.54 |
Valuation
ONCYhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (3)
- Newsglobenewswire.com·1d ago·Neutral
…xpects to add a new composition of matter patent covering “next generation” pelareorep SAN DIEGO, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today provided an update on its intellectual property strategy, outlining progress on new method of use patents and plans to expand its portfolio with composition of matter protection for a modified “next generation” pelareorep. Thes…
View source ↗ - Newsglobenewswire.com·15d ago·Neutral
…reates Immune Responses in Liver Cancer That Make Tumors Susceptible to Immunotherapy SAN DIEGO, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced data published in the Proceedings of the National Academy of Sciences show pelareorep's ability to change an immunologically inactive liver cancer tumor microenvironment into one that is immunologically active and pot…
View source ↗ - Newsglobenewswire.com·34d ago·Neutral
Oncolytics Biotech® Announces Positive Preclinical Results Combining Pelareorep with a Pan-RAS Inhibitor in Colorectal Cancer Oncolytics announced positive preclinical results evaluating pelareorep in combination with a pan-RAS inhibitor in a RAS-driven colorectal cancer model.
View source ↗
Earnings
Wed, Nov 11(in 4 weeks)
Consensus estimate $-0.07 per share
Typical surprise +16.7% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 12$-0.08 vs $-0.05miss
- Thu, May 14$-0.08 vs $-0.05miss
- Mon, Mar 30$-0.01 vs $-0.06beat
- Wed, Nov 12$-0.10 vs $-0.12beat
- Fri, Aug 8$-0.05 vs $-0.11beat
- Wed, May 14$-0.06 vs $-0.09beat
Estimates and results for ONCY via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ONCY officers and directors.
- Bought
- $363k
- Sold
- —
14 trades
0 trades
- Kelly Jaredbought
- Parsons James T.bought
- Kelly Jaredbought
- Look Kirkbought
- Pisano Waynebought
- Heineman Thomas Charlesbought
- Brown Deborah Margaretbought
- Hagerman Allisonbought
75 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ONCY.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.